BiotechTube
CanSense

CanSense

Swansea, United Kingdom· Est.
cansenseltd.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

CanSense is pioneering a liquid biopsy for the early detection of colorectal cancer, a leading global cause of cancer mortality. Its core technology integrates high-throughput laser spectroscopy with proprietary AI analytics to create a simple, label-free blood test designed to triage patients for colonoscopy. The company aims to address a significant unmet need by improving early detection rates, reducing healthcare costs, and saving lives. CanSense is a private, pre-revenue company advancing its diagnostic toward clinical validation and commercialization.

Oncology

Technology Platform

Label-free, high-throughput laser spectroscopy combined with proprietary artificial intelligence (AI) analytics to detect cancer-specific molecular signatures in blood.

Funding History

3
Total raised:$3.5M
Seed$1.5M
Seed$1.5M
Grant$500K

Opportunities

The massive global burden of colorectal cancer and limitations of current screening methods create a significant need for a non-invasive, cost-effective, and scalable diagnostic.
CanSense's estimated potential to save the NHS £250 million annually provides a powerful value proposition for rapid adoption by public healthcare systems.
The core spectroscopy-AI platform also holds potential for future expansion into other cancer types.

Risk Factors

Key risks include the failure of the test to achieve required sensitivity/specificity in large-scale clinical validation, challenges in securing reimbursement and integrating into clinical pathways, and intense competition from other liquid biopsy and diagnostic companies.
As a pre-revenue startup, the company is also dependent on securing ongoing funding to reach commercialization.

Competitive Landscape

CanSense competes in the growing liquid biopsy and early cancer detection market. Direct competitors include companies developing blood-based tests for colorectal cancer using genomic (e.g., Guardant Health, Freenome) or proteomic approaches. It also competes with standard screening tools like fecal tests and colonoscopy. Differentiation hinges on cost, accuracy, and the unique label-free spectroscopy method.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →